Mr. Rajesh (Raj) Mistry is Chief Financial Officer at Kenai Therapeutics. Previously, he was Advising Chief Financial Officer at Ryne Bio (Kenai’s predecessor) supporting the company’s $80+ million Series A financing and securement of grant funding from the California Institute for Regenerative Medicine (CIRM).

Mr. Mistry has approximately 20 years of healthcare finance experience in both privately-held and publicly-traded companies. He has advised several early-stage cell and gene therapy companies and other biotech and medtech companies with strategic finance and capital raising initiatives. Most recently, Mr. Mistry served as Chief Financial Officer of TriSalus Life Sciences (NASDAQ: TLSI), an immuno-oncology therapy company where he successfully guided the execution of the company’s private capital raising strategy that secured both equity and non-dilutive capital.

Previous to his Chief Financial Officer and advisory roles, Mr. Mistry led corporate M&A, directed corporate strategic finance and began his career in healthcare investment banking.

Mr. Mistry holds a Bachelor of Science in finance from Indiana University’s Kelley School of Business.